Otelixizumab
Based on 1 Customer Validation
Otelixizumab (ChAglyCD3) is an anti-human CD3 monoclonal antibody and can be used for the research of type 1 diabetes.
For research use only. We do not sell to patients.
- Purity : 99.64%
- CAS No.: 881191-44-2
- Molecular Weight:144.58 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Isotype
Human IgG1 lambda2
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
CD3
In Vitro
Otelixizumab (ChAglyCD3) has a dose-dependent accumulation and a half-life of about 1.5 days[2].
Otelixizumab targets the ε-chain of the CD3 T-lymphocyte surface receptor, which facilitates the activation of the autoreactive T-lymphocytes responsible for beta cell destruction[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c-huCD3e mice carrying the human CD3e chain[1]
-
Dosage:100 μg/mouse
-
Administration:Intravenous injection, once
-
Result:Induced secretion of lower amounts of IL-6. Exhibited up-regulation of regulatory T cells.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 lambda
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized CD3D-CD3E Heterodimer Protein, Human (HEK293, Fc, HY-P77610) can bind Otelixizumab. The EC50 for this effect is 1.824 ng/mL. -
Flow cytometric analysis of 106 Jurkat cells with Otelixizumab (HY-P99211, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor® 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 lambda1 (HY-P99992, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
CAS No. 881191-44-2
-
Appearance Liquid
-
Molecular Weight 144.58 kDa
-
Color Colorless to light yellow
-
SMILES
[Otelixizumab]
-
Synonyms
ChAglyCD3; TRX 4
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
Purity & Documentation
-
Data Sheet (259 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Kuhn C, et al. Human CD3 transgenic mice: preclinical testing of antibodies promoting immune tolerance. Sci Transl Med. 2011 Feb 2;3(68):68ra10. [Content Brief]
[2]. Guglielmi C, et al. Efficacy and safety of otelixizumab use in new-onset type 1 diabetes mellitus. Expert Opin Biol Ther. 2016 Jun;16(6):841-6. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)